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urologic tumour (12%), in the following sites: 150 in neck or 
chest, 70 in abdomen and 61 in pelvis. With a median follow-
up of 17 months (3-131) the overall response rate was 82% 
(Complete Response: 58%; Partial Response: 24%), with only 
3% of patients developing disease progression. DLT was 
recorded only in two patients, both treated with 50 Gy. Two-
year and 4-year local control were 71% and 62%, respectively. 
Two-year and 4-year metastases free survival were 46% and 
39%, respectively. 
 
Conclusion: SBRT in five fractions up to a dose of 50 Gy is 
well tolerated in different clinical settings. 
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Purpose or Objective: Oligometastatic prostate cancer is a 
state of limited metastatic disease (≤ 3 sites) that may be 
amenable to aggressive local therapy to achieve long term 
survival. The use of SBRT in this clinical setting has been 
reported to confer local control rate in excess of 90%, and 
encouraging progression free survival rate with no significant 
treatment –related toxicities1-4. One of the goals with this 
approach is to delay initiation of palliative systemic 
treatment, which can potentially impact negatively on 
quality of life. This study evaluated the outcomes of SBRT in 
our cohort.  
 
Material and Methods: Forty five patients diagnosed with 
oligometastatic prostate cancer (defined as a rising PSA and 
positive CT/PET choline scan) after definitive local therapy 
were treated with 1-2 courses of SBRT between July 2011 and 
July 2015. Over 90% of metastases were situated in lymph 
nodes or bone. Median dose was 30 Gy in 3 fractions, 
prescribed to the highest isodose covering the PTV. 
Retrospective data collection and analysis were performed 
for these patients. Kaplan-Meier was utilised to estimate 
progression free survival and overall survival and time to 
initiation of systemic treatment. Nineteen of the 35 patients 
with castration sensitive disease were treated with SBRT 
alone for their oligometastatic disease, 16 patients received 
SBRT and Androgen Deprivation Therapy (ADT) with median 
duration of 5 months. 10 patients who were castration 
resistant at the diagnosis of oligometastases were treated 
with SBRT with ongoing systemic treatment.  
 
Results: The median follow-up was 29 months (range 6-60 
months). Local control rate of lesions following SBRT 
treatment was 90%, overall progression free survival (PFS) 
was 38%, overall survival (OS) of 89% at 29 months. A 
reduction of pre-treatment PSA value of 48% and 75%, 
respectively was seen in castration sensitive patients who 
received SBRT alone and SBRT with ADT, and a 25% PSA 
reduction in castration resistant patients treated with SBRT 
and ADT. Median time to clinical progression was longer in 
castration sensitive patients treated with SBRT and ADT 
compared to SBRT alone (13 months vs 25 months). The 
median ADT-free survival for castration sensitive patients was 
16 months. Median time to initiation of next line therapy in 
castration resistant patients following SBRT treatment was 6 
months. No grade 3 or 4 treatment related toxicities 
reported. 
 
Conclusion: SBRT can provide a substantial delay to the next 
initiation of systemic therapy in castration sensitive patients 
whilst for castration resistant patients, there is a modest 
prolongation before initiation of subsequent therapy. Phase 
III data is lacking but will shortly be addressed in the SABR-
COMET and CORE trials.  
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Purpose or Objective: Radiobiological findings suggest an 
improvement in the therapeutic ratio for prostate cancer 
(PCa) treated with hypofractionation, compared with 
conventional fractionation. On this basis, in 2012 we 
activated a prospective study on extreme hypofractionated 
image-guided intensity modulated radiation therapy (IG-
IMRT) in organ-confined PCa. The aim of this study is the 
assessment of the feasibility of the proposed protocol – Give 
me five, in terms of acute and late toxicity and biochemical 
efficacy. 
 
Material and Methods: The study was performed within the 
Institutional Ethics Committee notification regarding 
hypofractionated IGRT for PCa. Inclusion criteria were: low 
to intermediate-risk (according to NCCN risk categories) 
histologically confirmed PCa; personalized indication for 
high-risk patients; prostate volume <100cm3; N0 and cM0; 
age >18 years; specific informed consent. In 10% of patients, 
multiparametric MRI was used for an improved definition of 
the patient anatomy, in addition to CT imaging. The nominal 
prescription dose was 32.5 or 35 Gy scheduled in 5 fractions 
on alternate days (therefore the name of protocol, “Give me 
five”), namely 6.5-7 Gy/fraction respectively, corresponding 
to a normalized total dose delivered at 2-Gy/fraction of 74.3 
or 85 Gy, respectively, estimating an α/β ratio of 1.5 Gy. 
Dose delivery was performed with VERO®-BrainLab-Mitsubishi 
or RapidArc®-Varian. No fiducial markers were implanted and 
set-up verification was performed daily by means of CBCT 
imaging. Toxicity was evaluated according RTOG/EORTC 
scales. The study was founded by Associazione Italiana per la 
Ricerca sul Cancro - AIRC, grant no. 13218. 
 
Results: Between April 2012 and May 2015, 166 patients were 
eligible. All patients completed the treatment. Median 
follow-up was 12.5 months (range 6-32.7 months). Fifty-
eitght, 83, 24 and 1 patients out of 166 were at low, 
intermediate, high and unknown risk, respectively. Median 
age was 74.3 years, median Gleason score was 6. Considering 
acute toxicity, 89.8%, 7.8%, 2.4% of patients had gastro-
intestinal G0, G1, G2 toxicity, respectively; 54.2%, 35.5%, 
9.6%, 0.6% of patients had genito-urinary G0, G1, G2, G4 
toxicity, respectively. Late toxicity and outcome were 
assessed in 129 patients (6 months minimum follow-up). 
Considering late toxicity, 3.1% and 0.8% of patients had 
gastro-intestinal G1 and G2 toxicity; 12.4%, 6.2% and 0.8% of 
patients had genito-urinary G1, G2, G3 toxicity, respectively. 
Clinical and biochemical progression prostate disease was 
observed in 2/129 of patients; currently, no evidence of 
prostate disease in 127/129 patients. 
